FDA Approves Pasatru to Halt Rogue Bone Growth in Ultra-Rare Disorder FOP

Imagine waking up to find that a swollen, painful flare-up on your shoulder has permanently locked the joint in place overnight, turning your own muscle into solid bone. For the roughly 900 people worldwide living with fibrodysplasia ossificans progressiva (FOP), this relentless, unpredictable ossification is a daily threat that gradually encases the body in a second skeleton.

Now, a major regulatory milestone is fundamentally changing that prognosis. The U.S. Food and Drug Administration has officially approved Pasatru (garetosmab-grts), a novel monoclonal antibody developed by Regeneron Pharmaceuticals, to halt this rogue bone formation in adults.[3][5]

The approval marks a watershed moment for the FOP community, introducing a highly targeted biologic therapy that directly neutralizes the biological trigger of the disease. Administered as a once-monthly intravenous infusion, Pasatru is the first treatment proven in clinical trials to dramatically reduce both the formation of new bone lesions and the painful flare-ups that precede them.

Unlike previous management strategies that primarily addressed symptoms, this therapy intervenes at the molecular level, offering patients a realistic chance to preserve their mobility and independence for decades longer than historical averages, which currently see most patients wheelchair-bound by age 30.[1][5]

To understand why Pasatru is so effective, it is necessary to look at the genetic root of FOP. The disorder is driven by a mutation in the ACVR1 gene, which controls a receptor involved in bone growth. Regeneron scientists discovered that in people with FOP, a specific protein called Activin A—which normally inhibits bone growth—inappropriately activates this mutated receptor, signaling the body's soft tissues to transform into bone.

Pasatru is a fully human monoclonal antibody explicitly designed to bind and neutralize Activin A. By intercepting this protein before it can interact with the mutated receptor, the drug effectively cuts the communication line that tells muscles and tendons to ossify.[2][4][6]

The clinical evidence supporting this mechanism is unusually robust for such a rare disease. In the Phase 3 OPTIMA trial, which enrolled 63 adults with active FOP, the results were definitive enough that an independent data monitoring committee recommended halting the placebo arm early.

Patients receiving the recommended 10 milligram per kilogram dose of Pasatru experienced a 90 percent reduction in new heterotopic ossification lesions over 56 weeks compared to those on a placebo. Furthermore, clinician-assessed flare-ups—the painful, hot swellings that signal new bone formation—plummeted by 88 percent in the high-dose group.[1][5]

For patients and their families, the practical application of this therapy is designed to minimize the burden of treatment. Because mobility is severely restricted as FOP progresses, Regeneron formulated Pasatru to be administered across various care settings, including home infusions where clinically appropriate.

The standard regimen involves a one-hour infusion every four weeks. If a patient struggles to tolerate the standard dose, physicians have the flexibility to reduce it to 3 milligrams per kilogram, which trial data showed was still highly effective at preventing new bone lesions, achieving a 94 percent reduction.[1][3][4]

However, manipulating the body's bone and tissue signaling pathways is not without systemic effects, and patients must navigate a specific side-effect profile. The most common adverse reactions observed during the OPTIMA trial included skin and soft tissue issues such as abscesses, acne, hair follicle inflammation, and oral ulcers. Some patients also experienced epistaxis, or severe nosebleeds, and madarosis, which is the loss of eyebrows or eyelashes. Because the drug can cause embryo-fetal toxicity, strict reproductive precautions are necessary, and its effects on male fertility remain an area of ongoing monitoring.[2][4][5]

Pasatru enters a treatment landscape that only recently saw its first dedicated therapy. In 2023, the FDA approved oral palovarotene (Sohonos), which works through a different mechanism to inhibit bone formation. The arrival of a second, highly efficacious biologic option provides critical flexibility for endocrinologists and rare-disease specialists managing FOP. While Pasatru is currently only approved for adults aged 18 and older, pediatric trials are slated to begin later this year, raising the hope that early intervention could eventually prevent the devastating accumulation of bone before it begins in childhood.[1][5][6]

The broader implications of this approval extend beyond FOP itself, serving as a powerful proof-of-concept for targeted biologics in ultra-rare genetic conditions. By successfully isolating and neutralizing a single rogue protein pathway, researchers have demonstrated that even the most complex and devastating structural diseases can be halted if the precise molecular trigger is identified. As the medical community watches the real-world rollout of Pasatru, the focus now shifts to ensuring equitable access and supporting the pediatric trials that could ultimately change the trajectory of the disease for the next generation.[3][6]